The RADAR Study: Week 48 Safety and Efficacy of RAltegravir Combined with Boosted DARunavir Compared to Tenofovir/Emtricitabine Combined with Boosted Darunavir in Antiretroviral-Naive Patients. Impact on Bone Health

• Published in: PloS one Vol. 9; no. 8; p. e106221
• Main Authors: Bedimo, Roger J., Drechsler, Henning, Jain, Mamta, Cutrell, James, Zhang, Song, Li, Xilong, Farukhi, Irfan, Castanon, Rosinda, Tebas, Pablo, Maalouf, Naim M.
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 29.08.2014; Public Library of Science (PLoS)
• Subjects: Acquired immune deficiency syndrome; Adenine - administration & dosage; Adenine - analogs & derivatives; Adult; AIDS; Antiretroviral agents; Antiretroviral drugs; Biology and Life Sciences; Bone (long); Bone density; Bone Density - drug effects; Bone mineral density; Bone turnover; CD4 antigen; Chi-square test; Cholesterol; Collagen; Darunavir; Deoxycytidine - administration & dosage; Deoxycytidine - analogs & derivatives; Dual energy X-ray absorptiometry; Effectiveness; Emtricitabine; Epidermal growth factor receptors; High density lipoprotein; HIV; HIV Infections - drug therapy; HIV Infections - metabolism; HIV Infections - pathology; HIV-1; Human immunodeficiency virus; Humans; Lipoproteins (high density); Long bone; Markers; Medicine and health sciences; Middle Aged; Mitochondria; Motivation; Organophosphonates - administration & dosage; Patients; Pyrrolidinones - administration & dosage; Radar; Raltegravir Potassium; Ritonavir; Statistical tests; Sulfonamides - administration & dosage; Tenofovir; Toxicity; United States > US; Texas

NRTI-sparing regimens may avoid long-term mitochondrial, bone and renal toxicities and maintain viral suppression. In the RADAR study, 85 antiretroviral-naïve HIV-infected patients were randomized to receive either raltegravir (RAL) (n = 42) or tenofovir/emtricitabine (TDF/FTC) (n = 43), each with r...